Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Retinoblastoma 2Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Psoriasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Sclerosis 1Melanoma 1Lymphatic Metastasis 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10Drug Therapy 9aflutinib 8Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × Platinum Compounds × Clear all
NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
120 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡